查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1925117

全球生物製藥合約服務市場預測至2032年：按服務類型、研究服務、技術、應用、最終用戶和地區分類

Biopharma Contract Services Market Forecasts to 2032 - Global Analysis By Service Type, Research Service, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球生物製藥合約服務市場規模將達到 270.1 億美元，到 2032 年將達到 519.7 億美元，預測期內複合年成長率為 9.8%。

生物製藥合約服務是指為生物技術和製藥公司提供的專業外包解決方案，旨在支援治療產品的研發和商業化。這些服務涵蓋廣泛的領域，包括合約研究組織 (CRO)、契約製造(CMO)、臨床試驗管理、法規遵循、分析測試和品質保證。透過利用外部專業知識和基礎設施，生物製藥公司可以加快藥物研發進程、降低營運成本並減少風險，同時確保符合嚴格的監管標準。這些夥伴關係能夠提供擴充性、柔軟性且創新的解決方案，從而提高全球生物製藥生態系統中臨床前研究、臨床試驗、生產和上市後支援等各階段的效率和準確性。

生物製藥和生物相似藥的需求不斷成長

生物製劑和生物相似藥需求的不斷成長是生物製藥合約服務市場的主要驅動力。慢性病和複雜疾病的日益普遍，以及標靶治療的興起，推動了外包研發和生產解決方案的需求。合約服務使生物製藥公司能夠加速生物製藥和生物相似藥的生產，最佳化臨床試驗效率，並確保符合監管要求。這種不斷成長的需求透過促進先進基礎設施、專業知識和可擴展的創新療法解決方案的獲取，推動了市場擴張。

高昂的資本和營運成本

高昂的資本投入和營運成本仍是限制市場發展的主要因素。建立先進的設施、維持合規營運以及實施先進技術都需要大量資金。由於預算限制，小規模的生技公司可能難以獲得全面的合約服務。此外，持續的專業人員配備、設備維護和品質保證也增加了營運負擔。這些財務和後勤壓力可能會延緩專案實施，並限制市場成長。

技術進步

技術進步為市場帶來了巨大的成長機會。自動化、高通量篩檢、分子診斷和先進分析技術的創新，使得藥物研發更快速精準。透過採用這些技術，合約服務供應商可以提高效率、減少錯誤，並為複雜的生物製藥、生物相似藥和個人化藥物提供可擴展的解決方案。運用尖端工具的公司能夠獲得競爭優勢，拓展服務範圍，從而為臨床前、臨床和商業化階段的持續成長奠定市場基礎。

供應鏈脆弱性

供應鏈脆弱性對市場構成重大威脅。由於依賴全球供應商提供原料、專用設備和先進試劑，市場極易受到地緣政治緊張局勢、監管變化和物流挑戰的影響。生產中斷和臨床試驗用品的延遲供應會影響進度、增加成本並損害品質標準。為了因應這些脆弱性，在高度監管且時間緊迫的產業中，強力的風險管理、策略採購和緊急時應對計畫對於維持服務連續性和保障市場成長至關重要。

新冠疫情的影響：

新冠疫情對市場產生了重大影響。它擾亂了供應鏈、臨床試驗和生產運營，同時加速了外包的普及，因為企業正在尋求靈活且擴充性的解決方案以維持研發效率。合約服務供應商在支持疫苗研發、快速檢測和治療方法創新方面發揮了關鍵作用。疫情驅動的數位轉型、遠端監控、分散式檢測和先進分析技術的應用進一步鞏固了市場地位。

預計在預測期內，臨床試驗領域將佔據最大的市場佔有率。

由於藥物研發計畫（尤其是生物製藥和生物相似藥）的複雜性和規模日益擴大，預計在預測期內，臨床試驗領域將佔據最大的市場佔有率。外包臨床試驗管理使生物製藥公司能夠獲得專業知識、提高患者招募率、確保符合監管要求並提升營運效率。因此，臨床試驗服務對於加快產品上市速度，同時維持高標準的資料品質和安全性至關重要。

在預測期內，製藥公司板塊將呈現最高的複合年成長率。

由於外包模式的日益普及，製藥公司預計將在預測期內實現最高成長率，這主要得益於其在最佳化研發效率、降低成本和規避複雜藥物開發風險方面所採取的策略。與生物製藥合約服務供應商合作，使製藥公司能夠利用先進的分析技術、法規支援和可擴展的生產能力。此外，對創新療法、生物相似藥和個人化醫療日益成長的需求，也進一步鞏固了製藥公司在全球市場擴張中的關鍵驅動力地位。

佔比最大的地區：

由於生物製藥行業的成長、臨床研究基礎設施的不斷完善、具成本效益的外包解決方案以及政府的支持性政策，亞太地區預計將在預測期內佔據最大的市場佔有率。生物製藥和生物相似藥產量的不斷成長，加上該地區熟練的勞動力和有利的監管改革，使其成為生物製藥合約服務的戰略要地。全球企業與當地企業之間的強大合作關係進一步鞏固了該地區的市場主導地位。

年複合成長率最高的地區：

在預測期內，由於生物製藥外包領域的技術創新，北美預計將實現最高的複合年成長率。該地區受益於許多大型製藥和生物技術公司的高度集中，這些公司尋求專業的合約服務，以加速臨床試驗、確保法規遵循並實現生產製造。對個人化醫療、生物相似藥和生物製藥日益成長的需求，加上健全的法規結構，使北美成為擴充性、高品質生物製藥合約解決方案快速成長的市場。

免費客製化服務資訊：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，對主要國家進行市場估算和預測，並計算複合年成長率（註：可行性需確認）。
  • 競爭標竿分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟進行基準分析

目錄

第1章執行摘要

第2章 前言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球生物製藥合約服務市場（依服務類型分類）

  • 委外研發機構(CRO) 服務
    • 臨床前服務
    • 監管事務服務
    • 臨床試驗服務
  • 受託製造廠商(CMO) 服務
    • 生物製藥生產
    • 細胞及基因治療製造
    • 小分子藥物生產
  • 合約開發與受託製造廠商(CDMO) 服務
    • 藥物開發服務
    • 分析和品質測試
    • 配方開發

6. 全球生物製藥合約服務市場（依研究服務分類）

  • 腫瘤學
  • 發炎/免疫學
  • 疫苗
  • 心臟病學
  • 其他

7. 全球生物製藥合約服務市場（依技術分類）

  • 生物製藥
  • 基因治療
  • 低分子
  • 細胞療法

8. 全球生物製藥合約服務市場（按應用領域分類）

  • 臨床試驗
  • 藥物研發
  • 藥物發現
  • 其他

9. 全球生物製藥合約服務市場（依最終用戶分類）

  • 製藥公司
  • 生技公司
  • 研究機構和學術中心

第10章：全球生物製藥合約服務市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Thermo Fisher Scientific Inc.
  • KBI Biopharma
  • Lonza Group AG
  • Cambrex Corporation
  • WuXi AppTec
  • Charles River Laboratories
  • WuXi Biologics
  • AbbVie Contract Manufacturing
  • Catalent Inc.
  • FUJIFILM Diosynth Biotechnologies
  • Samsung Biologics
  • Boehringer Ingelheim BioXcellence
  • Recipharm AB
  • Rentschler Biopharma SE
  • AGC Biologics
Product Code: SMRC33511

According to Stratistics MRC, the Global Biopharma Contract Services Market is accounted for $27.01 billion in 2025 and is expected to reach $51.97 billion by 2032 growing at a CAGR of 9.8% during the forecast period. Biopharma Contract Services refer to specialized outsourcing solutions provided to biotechnology and pharmaceutical companies to support the research, development, and commercialization of therapeutic products. These services encompass a wide spectrum, including contract research (CRO), contract manufacturing (CMO), clinical trial management, regulatory compliance, analytical testing, and quality assurance. By leveraging external expertise and infrastructure, biopharma companies can accelerate drug development timelines, reduce operational costs, and mitigate risk while maintaining compliance with stringent regulatory standards. These partnerships enable scalable, flexible, and innovative solutions, fostering efficiency and precision across preclinical research, clinical trials, manufacturing, and post-market support within the global biopharmaceutical ecosystem.

Market Dynamics:

Driver:

Rising Demand for Biologics & Biosimilars

The growing demand for biologics and biosimilars is a primary driver of the Biopharma Contract Services Market. Increasing prevalence of chronic and complex diseases, coupled with a shift toward targeted therapies, has intensified the need for outsourced development and manufacturing solutions. Contract services enable biopharma companies to accelerate biologics and biosimilar production, optimize clinical trial efficiency, and ensure regulatory compliance. This rising demand supports market expansion by facilitating access to advanced infrastructure, specialized expertise, and scalable solutions for innovative therapeutics.

Restraint:

High Capital & Operational Costs

High capital investment and operational costs remain significant restraints for the Market. Establishing advanced facilities, maintaining regulatory compliance, and implementing sophisticated technologies require substantial financial resources. Smaller biotechnology firms may face challenges accessing comprehensive contract services due to budget constraints. Additionally, the continuous need for skilled personnel, equipment maintenance, and quality assurance increases operational burdens. These financial and logistical pressures can slow adoption and limit market growth.

Opportunity:

Advancements in technology

Technological advancements present significant growth opportunities in the market. Innovations in automation, high-throughput screening, molecular diagnostics, and advanced analytics enable faster, more accurate drug development. By adopting these technologies, contract service providers can enhance efficiency, reduce errors, and offer scalable solutions for complex biologics, biosimilars, and personalized medicines. Companies that leverage cutting-edge tools gain competitive advantage and expand service offerings, positioning the market for sustained growth across preclinical, clinical, and commercial phases.

Threat:

Supply Chain Vulnerabilities

Supply chain vulnerabilities pose a notable threat to the market. Dependence on global suppliers for raw materials, specialized equipment, and advanced reagents exposes the sector to disruptions from geopolitical tensions, regulatory changes, or logistical challenges. Interruptions in production and delays in clinical trial materials can impact timelines, increase costs, and compromise quality standards. Such vulnerabilities necessitate robust risk management, strategic sourcing, and contingency planning to maintain service continuity and protect market growth in a highly regulated, time-sensitive industry.

Covid-19 Impact:

The COVID-19 pandemic significantly influenced the market. While it disrupted supply chains, clinical trials, and manufacturing operations, it also accelerated outsourcing adoption as companies sought flexible, scalable solutions to maintain R&D productivity. Contract service providers played a key role in supporting vaccine development, rapid testing, and therapeutic innovations. Pandemic-driven digital transformation and adoption of remote monitoring, decentralized trials, and advanced analytics further strengthened the market.

The clinical trials segment is expected to be the largest during the forecast period

The clinical trials segment is expected to account for the largest market share during the forecast period, due to increasing complexity and volume of drug development programs, particularly for biologics and biosimilars. Outsourcing clinical trial management enables biopharma companies to access specialized expertise, enhance patient recruitment, ensure regulatory compliance, and streamline operational efficiency. As a result, clinical trial services remain critical for accelerating time-to-market while maintaining high standards of data quality and safety.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate, due to rising outsourcing adoption to optimize R&D productivity, reduce costs, and mitigate risks associated with complex drug development. By partnering with biopharma contract service providers, pharmaceutical firms can leverage advanced analytical technologies, regulatory support, and scalable manufacturing capabilities. Increasing demand for innovative therapeutics, biosimilars, and personalized medicine further positions pharmaceutical companies as key drivers of market expansion globally.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to growing biopharmaceutical industry, expanding clinical research infrastructure, cost-effective outsourcing solutions, and supportive government initiatives. Increasing biologics and biosimilar production, coupled with the region's skilled workforce and favorable regulatory reforms, enhances its appeal as a strategic hub for biopharma contract services. Strong partnerships between global and local players further reinforce regional market dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to technological innovation in biopharma outsourcing. The region benefits from a high concentration of leading pharmaceutical and biotechnology companies seeking specialized contract services to accelerate clinical trials, regulatory compliance, and manufacturing. Increasing demand for personalized medicine, biosimilars, and biologics, alongside strong regulatory frameworks, positions North America as a rapidly growing market for scalable, high-quality biopharma contract solutions.

Key players in the market

Some of the key players in Biopharma Contract Services Market include Thermo Fisher Scientific Inc., KBI Biopharma, Lonza Group AG, Cambrex Corporation, WuXi AppTec, Charles River Laboratories, WuXi Biologics, AbbVie Contract Manufacturing, Catalent Inc., FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Boehringer Ingelheim BioXcellence, Recipharm AB, Rentschler Biopharma SE and AGC Biologics.

Key Developments:

In January 2026, TetraScience has entered a strategic collaboration with Thermo Fisher Scientific to accelerate scientific data transformation and AI enablement across biopharma laboratories. By integrating Thermo Fisher's instruments and informatics with TetraScience's AI-native data platform and intelligent workflows, the partnership aims to standardize fragmented lab data and power scalable, high-value AI use cases that enhance reproducibility, throughput, and decision-making in R&D and manufacturing.

In October 2025, Thermo Fisher Scientific's PPD clinical research arm has forged a new R&D partnership with AstraZeneca's BioVentureHub in Gothenburg, Sweden, co-locating teams to collaborate on projects in chromatography, molecular genomics and proteomics, boosting innovation and strengthening the life science ecosystem.

Service Types Covered:

  • Contract Research Organization (CRO) Services
  • Contract Manufacturing Organization (CMO) Services
  • Contract Development and Manufacturing Organization (CDMO) Services

Research Services Covered:

  • Oncology
  • Inflammation & Immunology
  • Vaccines
  • Cardiology
  • Other Research Services

Technologies Covered:

  • Biologics
  • Gene Therapy
  • Small Molecules
  • Cell Therapy

Applications Covered:

  • Clinical Trials
  • Drug Development
  • Drug Discovery
  • Other Applications

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Research Institutes & Academic Centers

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biopharma Contract Services Market, By Service Type

  • 5.1 Introduction
  • 5.2 Contract Research Organization (CRO) Services
    • 5.2.1 Preclinical Services
    • 5.2.2 Regulatory Affairs Services
    • 5.2.3 Clinical Trial Services
  • 5.3 Contract Manufacturing Organization (CMO) Services
    • 5.3.1 Biologic Manufacturing
    • 5.3.2 Cell and Gene Therapy Manufacturing
    • 5.3.3 Small Molecule Manufacturing
  • 5.4 Contract Development and Manufacturing Organization (CDMO) Services
    • 5.4.1 Drug Development Services
    • 5.4.2 Analytical & Quality Testing
    • 5.4.3 Formulation Development

6 Global Biopharma Contract Services Market, By Research Service

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Inflammation & Immunology
  • 6.4 Vaccines
  • 6.5 Cardiology
  • 6.6 Other Research Services

7 Global Biopharma Contract Services Market, By Technology

  • 7.1 Introduction
  • 7.2 Biologics
  • 7.3 Gene Therapy
  • 7.4 Small Molecules
  • 7.5 Cell Therapy

8 Global Biopharma Contract Services Market, By Application

  • 8.1 Introduction
  • 8.2 Clinical Trials
  • 8.3 Drug Development
  • 8.4 Drug Discovery
  • 8.5 Other Applications

9 Global Biopharma Contract Services Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Biotechnology Companies
  • 9.4 Research Institutes & Academic Centers

10 Global Biopharma Contract Services Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 KBI Biopharma
  • 12.3 Lonza Group AG
  • 12.4 Cambrex Corporation
  • 12.5 WuXi AppTec
  • 12.6 Charles River Laboratories
  • 12.7 WuXi Biologics
  • 12.8 AbbVie Contract Manufacturing
  • 12.9 Catalent Inc.
  • 12.10 FUJIFILM Diosynth Biotechnologies
  • 12.11 Samsung Biologics
  • 12.12 Boehringer Ingelheim BioXcellence
  • 12.13 Recipharm AB
  • 12.14 Rentschler Biopharma SE
  • 12.15 AGC Biologics

List of Tables

  • Table 1 Global Biopharma Contract Services Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Biopharma Contract Services Market Outlook, By Service Type (2024-2032) ($MN)
  • Table 3 Global Biopharma Contract Services Market Outlook, By Contract Research Organization (CRO) Services (2024-2032) ($MN)
  • Table 4 Global Biopharma Contract Services Market Outlook, By Preclinical Services (2024-2032) ($MN)
  • Table 5 Global Biopharma Contract Services Market Outlook, By Regulatory Affairs Services (2024-2032) ($MN)
  • Table 6 Global Biopharma Contract Services Market Outlook, By Clinical Trial Services (2024-2032) ($MN)
  • Table 7 Global Biopharma Contract Services Market Outlook, By Contract Manufacturing Organization (CMO) Services (2024-2032) ($MN)
  • Table 8 Global Biopharma Contract Services Market Outlook, By Biologic Manufacturing (2024-2032) ($MN)
  • Table 9 Global Biopharma Contract Services Market Outlook, By Cell and Gene Therapy Manufacturing (2024-2032) ($MN)
  • Table 10 Global Biopharma Contract Services Market Outlook, By Small Molecule Manufacturing (2024-2032) ($MN)
  • Table 11 Global Biopharma Contract Services Market Outlook, By Contract Development and Manufacturing Organization (CDMO) Services (2024-2032) ($MN)
  • Table 12 Global Biopharma Contract Services Market Outlook, By Drug Development Services (2024-2032) ($MN)
  • Table 13 Global Biopharma Contract Services Market Outlook, By Analytical & Quality Testing (2024-2032) ($MN)
  • Table 14 Global Biopharma Contract Services Market Outlook, By Formulation Development (2024-2032) ($MN)
  • Table 15 Global Biopharma Contract Services Market Outlook, By Research Service (2024-2032) ($MN)
  • Table 16 Global Biopharma Contract Services Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 17 Global Biopharma Contract Services Market Outlook, By Inflammation & Immunology (2024-2032) ($MN)
  • Table 18 Global Biopharma Contract Services Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 19 Global Biopharma Contract Services Market Outlook, By Cardiology (2024-2032) ($MN)
  • Table 20 Global Biopharma Contract Services Market Outlook, By Other Research Services (2024-2032) ($MN)
  • Table 21 Global Biopharma Contract Services Market Outlook, By Technology (2024-2032) ($MN)
  • Table 22 Global Biopharma Contract Services Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 23 Global Biopharma Contract Services Market Outlook, By Gene Therapy (2024-2032) ($MN)
  • Table 24 Global Biopharma Contract Services Market Outlook, By Small Molecules (2024-2032) ($MN)
  • Table 25 Global Biopharma Contract Services Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 26 Global Biopharma Contract Services Market Outlook, By Application (2024-2032) ($MN)
  • Table 27 Global Biopharma Contract Services Market Outlook, By Clinical Trials (2024-2032) ($MN)
  • Table 28 Global Biopharma Contract Services Market Outlook, By Drug Development (2024-2032) ($MN)
  • Table 29 Global Biopharma Contract Services Market Outlook, By Drug Discovery (2024-2032) ($MN)
  • Table 30 Global Biopharma Contract Services Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 31 Global Biopharma Contract Services Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Biopharma Contract Services Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 33 Global Biopharma Contract Services Market Outlook, By Biotechnology Companies (2024-2032) ($MN)
  • Table 34 Global Biopharma Contract Services Market Outlook, By Research Institutes & Academic Centers (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.